| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Kinsmen Laboratory of Neurological Research and the Neurodegenerative Disorders Centre (Drs. Tooyama, Kawamata, Walker, Yamada, E.G. McGeer, and P.L. McGeer), The University of British Columbia, Vancouver, BC, Canada; the Institute of Molecular Keurobiology (Drs. Hanai and Kimura), Ship University of Medical Science, Otsu, Shiga, Japan; and the Takeda Biology Research Laboratory (Drs. Iwane and Igarashi), Takeda Chemical Industry, Osaka, Japan.
Basic fibroblast growth factor (bFGF) has a neurotrophic effect on mesencephalic dopaminergic neurons in vitro and in vivo. To explore whether an abnormality in bFGF expression occurs in Parkinson's disease (PD), we examined the substantia nigra (SN) of six PD and eight control cases immunohistochemically using a monoclonal antibody to bFGF. The mean number of melanin-positive neurons in sections of PD SN was 30.3% of the control mean, but the number of bFGF-immunopositive neurons was only 4.7% of the control mean. bFGF-immunorcactivity was present in only 8.2% of PD, but in 93.7% of control melanin-positive neurons. These results suggest a profound depletion of bFGF in surviving dopaminergic neurons of the SN in PD, and this depletion may be related to the disease process.
Address correspondence and reprint requests to Dr. Patrick L. McGeer, The University of British Columbia, Kinsmen Laboratory of Neurological Research, 2255 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Supported by grants from the Japan Foundation for Aging and Health, the MRC, the Parkinson Foundation of Canada, and the Alzheimer Society of British Columbia.
Received April 29, 1992. Accepted for publication in final form July 8, 1992.
This article has been cited by other articles:
|
|
 |
|
  C. Cristina, G. Diaz-Torga, A. Gongora, M. C. Guida, M. I. Perez-Millan, A. Baldi, and D. Becu-Villalobos Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1341 - E1351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Timmer, K. Cesnulevicius, C. Winkler, J. Kolb, E. Lipokatic-Takacs, J. Jungnickel, and C. Grothe Fibroblast Growth Factor (FGF)-2 and FGF Receptor 3 Are Required for the Development of the Substantia Nigra, and FGF-2 Plays a Crucial Role for the Rescue of Dopaminergic Neurons after 6-Hydroxydopamine Lesion J. Neurosci., January 17, 2007; 27(3): 459 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Li, H. Guo, X. Luo, J. Sheng, S. Yang, Y. Yin, J. Zhou, and J. Zhou Apomorphine-induced activation of dopamine receptors modulates FGF-2 expression in astrocytic cultures and promotes survival of dopaminergic neurons FASEB J, June 1, 2006; 20(8): 1263 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-L. Hsuan, H. M. Klintworth, and Z. Xia Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci., April 26, 2006; 26(17): 4481 - 4491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. -L. Kuan and R. A. Barker New Therapeutic Approaches to Parkinson's Disease Including Neural Transplants Neurorehabil Neural Repair, September 1, 2005; 19(3): 155 - 181. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Dono Fibroblast growth factors as regulators of central nervous system development and function Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R867 - R881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bikfalvi, S. Klein, G. Pintucci, and D. B. Rifkin Biological Roles of Fibroblast Growth Factor-2 Endocr. Rev., February 1, 1997; 18(1): 26 - 45. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
